BioSpace News Archive

Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes

Adocia today announced that five abstracts featuring applications of its BioChaperone® platform technology have been accepted for presentation at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) being held October 1-5, 2018 in Berlin, Germany.

September 29, 2018
·
6 min read
Myriad Announces New GeneSight® Study Published in Personalized Medicine

Study based upon OptumInsight data showed More Than $6,200 in First Year Healthcare Costs Compared to Treatment-As-Usual for Patients with Depression

September 29, 2018
·
7 min read
Business

IU-Regenstrief 1 of 11 Awards for Next Generation of Learning Health System Researchers

Collaboration to receive $3.4 million over 5 years from AHRQ and PCORI

September 29, 2018
·
5 min read
Deals

Clinigen Group plc Acquisition of CSM for initial consideration of $150 million

Accretive acquisition significantly strengthens Clinigen’s competitive positioning with specialist packaging, labelling, warehousing and distribution capabilities in Europe & the US

September 29, 2018
·
6 min read
Business

GENFIT: Further Details on Management Changes

GENFIT today provides further details on the management changes announced in its September 24, 2018 press release.

September 29, 2018
·
4 min read
Innovation Industries joins €18m Series A financing round of A-MANSIA, a leading microbiome company

The financing round will be used to progress development pipeline based on the key bacterial symbiont Akkermansia muciniphila

September 29, 2018
·
5 min read
Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October 2018

Immunicum AB (publ; IMMU.ST) today announced that Company leadership will present at upcoming regulatory affairs, industry and scientific conferences in October.

September 29, 2018
·
1 min read
Business

Clinigen Group plc - DIVERSIFIED PORTFOLIO DRIVES STRONG FINANCIAL RESULTS

Clinigen Group plc has today published its full year results for the year ended 30 June 2018.

September 29, 2018
·
5 min read
FDA

Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-CD47 Monoclonal Antibody IBI-188

Innovent Biologics, Inc. announced yesterday that its IND application for IBI-188, a fully human anti-CD47 monoclonal antibody (mAb) drug candidate, has been approved by the US Food & Drug Administration (FDA) to initiate clinical trials for patients with advanced malignancies and lymphomas.

September 29, 2018
·
4 min read
Drug Development

First Patient Dosed in a Phase III Trial of Anti-PD-1 Antibody Sintilimab as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer

Innovent Biologics, Inc. announced today that the first patient has been dosed in a phase III clinical trial (ORIENT-12) studying sintilimab, a fully human anti-PD-1 monoclonal antibody (IBI-308), as first-line treatment for patients with previously untreated squamous non-small cell lung cancer (NSCLC).

September 29, 2018
·
6 min read